Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$20.30
+1.1%		$18.31
$9.56
▼
$21.17
$6.41B1.222.78 million shs2.25 million shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$159.56
-2.1%		$166.48
$72.65
▼
$200.00
$6.56B-1.23203,207 shs184,763 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$99.96
+0.3%		$100.71
$49.67
▼
$111.86
$6.50B-0.06976,694 shs705,952 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$9.08
-1.8%		$8.46
$5.25
▼
$11.33
$1.69B0.533.14 million shs1.38 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
+1.15%+2.68%+12.40%+18.37%+95.57%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-2.10%-4.64%-0.68%+8.82%+117.09%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.31%+0.22%-0.84%-9.04%+93.61%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-1.84%-0.22%+5.83%+9.66%+13.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$20.30
+1.1%		$18.31
$9.56
▼
$21.17
$6.41B1.222.78 million shs2.25 million shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$159.56
-2.1%		$166.48
$72.65
▼
$200.00
$6.56B-1.23203,207 shs184,763 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$99.96
+0.3%		$100.71
$49.67
▼
$111.86
$6.50B-0.06976,694 shs705,952 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$9.08
-1.8%		$8.46
$5.25
▼
$11.33
$1.69B0.533.14 million shs1.38 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
+1.15%+2.68%+12.40%+18.37%+95.57%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-2.10%-4.64%-0.68%+8.82%+117.09%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.31%+0.22%-0.84%-9.04%+93.61%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-1.84%-0.22%+5.83%+9.66%+13.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
2.90
Moderate Buy$21.003.45% Upside
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.64
Moderate Buy$218.7337.08% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.29
Hold$108.118.15% Upside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.43
Hold$12.8040.97% Upside

Current Analyst Ratings Breakdown

Latest XERS, BLTE, AMRX, and LNTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/1/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/25/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
9/23/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$27.00
9/17/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$16.00 ➝ $20.00
9/10/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C+) ➝ Hold (C)
9/10/2026
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$12.00 ➝ $16.00
9/9/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$220.00 ➝ $234.00
9/9/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
9/9/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$23.00
9/9/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$23.00
9/8/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$245.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$3.02B2.15$1.58 per share12.85($0.23) per share-88.26
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$20.54 per shareN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.54B4.23$6.40 per share15.61$16.43 per share6.08
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$291.85M5.67$0.10 per share92.35$0.08 per share113.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$72.06M$0.4941.4318.802.365.05%-584.46%7.78%N/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.73N/A175.34N/AN/A-11.84%-11.62%11/9/2026 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$233.56M$4.1424.1418.31N/A17.69%28.10%14.35%11/5/2026 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$550K-$0.11N/A30.27N/A-5.12%338.21%3.50%11/5/2026 (Estimated)

Latest XERS, BLTE, AMRX, and LNTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.73-$0.54+$0.19-$0.70N/AN/A
8/6/2026Q2 2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.30$1.55+$0.25$1.11$363.23 million$388.18 million
8/6/2026Q2 2026
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$0.0121-$0.18-$0.1921-$0.18$90.13 million$92.10 million
7/30/2026Q2 2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$0.24$0.30+$0.06$0.18N/A$796.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/AN/AN/AN/AN/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
77.65
2.20
1.44
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
33.56
33.56
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.43
3.06
2.89
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
17.00
1.45
1.02

Institutional Ownership

CompanyInstitutional Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
31.82%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
17.30%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.70%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
8,500319.35 million264.11 millionOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
4140.27 million34.92 millionNot Optionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1,19365.27 million64.16 millionOptionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
435182.32 million174.39 millionOptionable

Recent News About These Companies

Xeris Biopharma (NASDAQ:XERS) Stock: Insider Steven Pieper Sells 5,000 Shares
October 2 at 5:22 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-xeris-biopharma-nasdaq-xers-stock-insider-steven-pieper-sells-5000-shares-2026-10-02/
Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock
October 2 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-xeris-biopharma-nasdaq-xers-insider-kevin-mcculloch-sells-15000-shares-of-stock-2026-10-02/
Xeris Biopharma (NASDAQ:XERS) Insider Sells 16,666 Shares of Stock
October 2 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-xeris-biopharma-nasdaq-xers-insider-sells-16666-shares-of-stock-2026-10-02/
Xeris Biopharma (NASDAQ:XERS) Stock: Insider Kevin Mcculloch Sells 25,000 Shares
October 1 at 4:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073135
Update: Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition
September 30 at 8:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/market-chatter-lundbeck-said-explore-121329291.html
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $250,000.00 in Stock
September 30 at 4:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-xers-insider-buying-and-selling-2026-09-30/
Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lundbeck-approaches-xeris-biopharma-over-201736994.html
Xeris Biopharma reportedly draws takeover interest — but firm says it’s not for sale
September 29, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/xeris-biopharma-reportedly-draws-takeover-interest-but-firm-says-it-s-not-for-sale/ar-AA2ddCbN
Xeris Biopharma (NASDAQ:XERS) Insider Sells 25,000 Shares of Stock
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-xeris-biopharma-nasdaq-xers-insider-sells-25000-shares-of-stock-2026-09-29/
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
September 29, 2026  |  marketscreener.comM
Xeris Biopharma jumps on report of interest from H Lundbeck
September 29, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/xeris-biopharma-jumps-on-report-of-interest-from-h-lundbeck/ar-AA2ddwkh
Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - What's Next?
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xeris-biopharma-nasdaq-xers-hits-new-12-month-high-whats-next-2026-09-29/
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2% - Here's What Happened
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xeris-biopharma-nasdaq-xers-shares-up-52-heres-what-happened-2026-09-28/
1,397,050 Shares of Xeris Biopharma Holdings, Inc. $XERS Acquired by Bank of America Corp DE
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-1397050-shares-of-xeris-biopharma-holdings-inc-xers-acquired-by-bank-of-america-corp-de-2026-09-27/
Corient Private Wealth LP Acquires 184,126 Shares of Xeris Biopharma Holdings, Inc. $XERS
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-acquires-184126-shares-of-xeris-biopharma-holdings-inc-xers-2026-09-26/
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of "Hold" by Analysts
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-xeris-biopharma-holdings-inc-nasdaq-xers-given-average-recommendation-of-hold-by-analysts-2026-09-21/
Xeris Biopharma stock gains on higher targets and August results
September 19, 2026  |  ad-hoc-news.deA
Wall Street Zen Upgrades Xeris Biopharma (NASDAQ:XERS) to Buy
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-upgrades-xeris-biopharma-nasdaq-xers-to-buy-2026-09-19/
Xeris Biopharma Holdings stock gains after strong Q2 revenue growth
September 18, 2026  |  ad-hoc-news.deA
Squarepoint Ops LLC Has $2.90 Million Holdings in Xeris Biopharma Holdings, Inc. $XERS
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-has-290-million-holdings-in-xeris-biopharma-holdings-inc-xers-2026-09-14/
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy - Slideshow
September 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945701-xeris-biopharma-holdings-inc-xers-discusses-xpminus-8121-program-overview-phase-3-study

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amneal Pharmaceuticals stock logo

Amneal Pharmaceuticals NASDAQ:AMRX

$20.30 +0.23 (+1.15%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$20.45 +0.15 (+0.74%)
As of 10/2/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$159.56 -3.42 (-2.10%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$159.46 -0.09 (-0.06%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$99.96 +0.31 (+0.31%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$99.90 -0.06 (-0.07%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$9.08 -0.17 (-1.84%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$9.16 +0.08 (+0.94%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas